Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice by Ruffini, Pier A et al.
Ruffini et al. Journal of Translational Medicine 2014, 12:207
http://www.translational-medicine.com/content/12/1/207RESEARCH Open AccessTargeted DNA vaccines eliciting crossreactive
anti-idiotypic antibody responses against human
B cell malignancies in mice
Pier Adelchi Ruffini1,4*, Audun Os1,4, Riccardo Dolcetti3, Geir E Tjønnfjord2,4, Ludvig A Munthe1,4
and Bjarne Bogen1,4,5*Abstract
Background: Therapeutic idiotypic (Id) vaccination is an experimental treatment for selected B cell malignancies.
A broader use of Id-based vaccination, however, is hampered by the complexity and costs due to the
individualized production of protein vaccines. These limitations may be overcome by targeted DNA vaccines
encoding stereotyped immunoglobulin V regions of B cell malignancies. We have here investigated whether
such vaccines might elicit cross-reactive immune responses thus offering the possibility to immunize subsets of
patients with the same vaccine.
Methods: Fusion vaccines targeting patient Id to mouse Major Histocompatibility Complex (MHC) class II
molecules (chimeric mouse/human) or chemokine receptors (fully human) on antigen-presenting cells (APC) were
genetically constructed for two Chronic Lymphocytic Leukemia (CLL) patients and one prototypic stereotyped
B-cell receptor (BCR) commonly expressed by Hepatitis C Virus (HCV)-associated Non Hodgkin Lymphoma (NHL).
The A20 murine B lymphoma cells were engineered to express prototypic HCV-associated B cell lymphoma BCR.
Anti-Id antibody responses were studied against stereotyped and non-stereotyped BCRs on CLL patients’ cells as
well as transfected A20 cells.
Results: DNA vaccination of mice with Id vaccines that target APC elicited increased amounts of antibodies
specific for the patient’s Id as compared with non targeted control vaccines. Anti–Id antibodies cross-reacted
between CLL cells with closely related BCR. A20 cells engineered to express patients’ V regions were not
tumorigenic in mice, preventing tumor challenge experiments.
Conclusions: These findings provide experimental support for use of APC-targeted fusion Id DNA vaccines for
the treatment of B cell lymphoma and CLL that express stereotyped BCRs.
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B cell malignancies express a highly tumor-specific antigen,
the variable (V) regions of the monoclonal immunoglobu-
lin (Ig), which contain antigenic determinants called idio-
topes collectively known as idiotype (Id). Protein Id
vaccination has been pursued as a therapeutic approach to
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unless otherwise stated.and clinical responses have been detected [1], whereas
demonstration of clinical benefit is so far limited to follicu-
lar lymphoma [2,3].
Because of the very nature of the antigen (Ag) (i.e., Id),
large scale clinical application of protein Id vaccination is
limited by the need to prepare a custom-made vaccine for
each and every patient. Overcoming this problem, DNA
vaccination holds promise to streamline tailor-made vac-
cine manufacture by circumventing the need for purifica-
tion of Ig protein (or derivatives thereof), conjugation to
carrier protein (e.g. KLH) and administration of adjuvants.
However, although effective in rodents, DNA vaccinationLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of CLL patients’ BCR
CLL pt. isotype IGHV IGHD IGHJ IGLV IGLJ
103 IgMλ 3-48*02 2-2*01 4*01 3-21*01 3*02
106 IgMλ 3-23*01 4-23*01 4*02 3-21*01 1*01
107 IgMκ 3-30*02 4-17*01 5*02 4-1*01 4*01
111 IgMλ − κ 3-53*01 n.a. 1*01 3-21*01 λ 3*02
3-20*01 κ 1*01
116 IgMκ 4-59*01 2-15*01 2*01 3-20*01 1*01
n.a.: no results in IMGT/V-QUEST.
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low potency of vaccines [4]. The poor immunogenicity of
DNA vaccination can be improved by several means such
as improved vector design and efficient electroporation
[5]. Another strategy is based on the finding that targeting
of Ag to antigen-presenting cells (APC) enhances im-
munogenicity, as shown for chemical antibody (Ab)-Ag
conjugates [6,7] and Ab-Ag fusion proteins [8,9]. Thus,
we [10] and others [11,12] cloned DNA constructs encod-
ing proteins that target Ag to APC. When such constructs
were injected s.c. or i.m., combined with electroporation,
transfected host cells secreted fusion proteins that tar-
geted APC for enhanced immune responses [10]. In our
previous studies, we used homodimeric Ig-based vaccines
(Vaccibodies, VB), each chain consisting of a targeting unit,
a dimerization unit and an antigenic unit. The dimerization
unit consists of a shortened hinge region from hIgG3
whereas the N-terminal targeting unit can consist of either
single chain fragment variable (scFv) specific for surface
molecules on APC such as mouse MHC class II [10],
mouse CD40 [13], human TLR2 and CD14 [14], or natural
ligands such as the mouse chemokines CCL3 (mCCL3)
and CCL5 (mCCL5) [15] and human CCL3 [16]. Depend-
ing on targeting strategy, such VB proteins had a 10–
10,000 fold increased efficiency to stimulate CD4+ T cells
in vitro in mice [10,13,15,16] and humans [14,16]. More-
over, DNAVaccibodies elicited superior antibody and Tcell
responses in mice, as well as greatly enhanced tumor pro-
tection [10,13,15,16]. In a stepwise, translational endeavour,
the first fully murine Vaccibodies [10] have been extended
to chimeric murine/human Vaccibodies, including tailor-
made Vaccibodies for multiple myeloma patients [17].
A complementary strategy to streamline clinical Id
vaccination is to exploit the high similarity of Ig V re-
gions expressed by molecularly identified subgroups of
patients with B cell malignancies. For example, the mo-
lecular characterization of Hepatitis C Virus (HCV) re-
lated lymphomas showed that more than 70% of these
cases expressed either IGKV3-20 or IGKV3-15 light
chains [18-20], with a high degree of homology between
individual lymphomas. Moreover, IGHV1-69 is expressed
as the partner of IGKV3-20 or IGKV3-15 in up to 70%
of HCV-related lymphomas [18,20]. Such commonly
expressed B cell receptors (BCR) are called stereotyped
receptors. Stereotyped BCRs are found also in several
non HCV-associated B cell malignancies, such as MALT
lymphomas [21-23] and Chronic Lymphocytic Leukemia
(CLL) [24-26]. The analysis of VH CDR3 in more than
7000 VH (IGHV-IGHD-IGHJ) sequences from patients
with CLL has established that CLL comprises two distinct
categories: one with stereotyped and the other with het-
erogeneous BCR, in an approximate ratio of 1:2 [27].
Thus, it could be envisioned that a number of off-the-
shelf Id vaccines for molecularly identifiable subgroups ofpatients could be developed, obviating the need to tailor-
make Id-vaccines for every patient. Although it is not
known whether these Ids are immunogenic in the major-
ity of patients, such off-the-shelf Id vaccines could cover
up to 30% of patients with selected B cell malignancies,
thus affording substantial savings in time and costs associ-
ated with Id vaccine manufacture.
On these premises, we have here produced fully hu-
man chemokine-Id fusion DNA Vaccibodies which due
to cross-species reactivity of chemokines could be tested
as DNA vaccines in mice. Moreover, using a panel of
CLL patients’ cells and a mouse model for HCV-associated
B cell lymphomas we explored the possibility of indu-
cing cross-reactive anti-Id antibody responses following
immunization with VB expressing a stereotyped B cell
receptor.
Methods
Patient material
Patients diagnosed with CLL (see Table 1) were seen at
the Department of Haematology outpatient clinic, Oslo
University Hospital, Rikshospitalet, Oslo, Norway. Blood
samples from 5 patients were procured following written
informed consent using protocols approved by the Regional
Committee for Medical and Research Ethics, South-East
Norway. Blood samples were procured in tubes containing
ACD as anticoagulant. Experiments were conducted on
purified mononuclear blood cells.
Flow cytometry
Cells were stained with primary reagents and appropri-
ate secondary reagents or control as indicated. The fol-
lowing biotinylated mAbs were used: anti human IgG
(HP6017, Zymed), anti mouse IgD (TIB149, ATCC), anti
mouse Ck (clone 187.1), anti mouse IgG1a (clone 10.9,
BD Pharmingen), anti mouse IgG2aa (clone 8.3, BD
Pharmingen), anti mouse IgG2ab (clone 5.7, BD Phar-
mingen). Quantification of surface antigen on CLL cells
was performed using mouse mAbs targeting human λ
(clone 4C2) and human κ L chains (clone A8B5), and hu-
man IgM (clone 1030) from Diatec, Oslo, Norway, and the
bead based Cellquant Calibrator kit (BioCytex, Marseille,
France) according to the manufacturer’s guidelines [28].
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cytometry files were analyzed on CellQuest (BD) and
Weasel v3.0 (http://www.wehi.edu.au).
Mice and cell lines
BALB/c mice were obtained from Taconic (Ry, Denmark).
B10.D2.C-TCRαa/Bo (H-2d, Ig haplotype IgH-Cb) mice
were bred in house. These congenic mice are identical
to B10.D2 except being congenic for the TCRαa region
[29]. The studies were approved by the National Com-
mittee for Animal Experiments (Oslo, Norway). HEK
293E cells were from ATCC. The murine lymphoma
Esb/MP cells [30] were kindly provided by Jo Van Damme
(Leuven, Belgium). The human Burkitt’s lymphomas DG-
75 [31] and PA682 [32] were obtained from ATCC and
kindly provided by Keith Thompson (Oslo, Norway),
respectively.
Identification of VH and VL genes from CLL patients and
assembly of scFv
VH and VL tumor-specific genes were cloned from prep-
arations of cDNA from PBMCs of each patient. Tumor-
specific transcripts were identified by PCR as previously
described [33].
Sequence data were analyzed using the IMGT database
(http://www.imgt.org) and the IMGT/V-QUEST tool [34].
Nucleotide sequences were aligned using BLAST (http://
blast.ncbi.nlm.nih.gov/). Amino acid sequences were aligned
using clustal omega (http://www.ebi.ac.uk/Tools/msa/clus
talo/) and GeneDoc (http://nrbsc.org/gfx/genedoc/) for ana-
lysis of conservative, semi-conservative and non conserva-
tive changes. Tumor-specific VH and VL genes from CLL
patients were arranged in a single chain variable region
fragment (scFv) in VH-VL orientation by PCR Soeing
(Synthesis by Overlap Extension) essentially as described
previously [33].
Assembly of stereotyped scFv for Hepatitis C virus-associated
B cell lymphomas
Plasmids encoding V (D) JH (VH1-69, VD3-22, VJ4) and
VJκ (VK3-20, VJ1) sequences from patients 1 and 2, re-
spectively, were kindly provided by V. De Re (Aviano,
Italy) and assembled into scFv as described above. This
association has been shown to be representative of ste-
reotyped Id molecules expressed by up to 70% of B cell
malignancies associated with HCV chronic infection
[18,20].
Assembly of patient-specific and cross-reactive
Vaccibodies
The resulting scFv from individual CLL patients or the
prototypic stereotyped BCR from HCV-associated B
lymphoma were cloned C-terminal as antigenic units into
the previously described VB format [10]. In Vaccibodiesused in this study, the N-terminal targeting unit consisted
either of a mouse scFv from the 14-4-4S mAb specific
for I-E mouse MHC class II molecules [10], or the hu-
man chemokine LD78β (CCL3-L1) which binds CCR1,
CCR3 and CCR5 [16]. Control non-targeted Vaccibo-
dies encoded a mouse scFv specific for the hapten NIP
(5-iodo-4-hydroxy-3-nitrophenylacetyl), an antigen which
is not found in the mouse tissue [10]. The dimerization
unit consisted of a shortened hinge (h1 + h4) and CH3 of
human IgG3 [10].
Vaccine protein production and assessment of targeting
properties
Expression and function of chimeric VB constructs was
determined on supernatants from transiently transfected
HEK 293E cells. To comparatively measure concentra-
tion of Vaccibodies expressing different targeting and
antigenic units, an ELISA detecting the presence of
human IgG3CH3 in the dimerization unit was set up:
mAb MCA878G (binds human IgG3CH3, AB Serotec) as
coat and biotinylated mAb HP6017 (binds to a different
epitope in human IgG3CH3) for detection. Binding to
MHC class II was verified by admixing I-Ed-specific VB-
containing supernatants and BALB/c (I-Ed+) A20 B
lymphoma cells. Bound VB proteins were detected as
previously described [17]. NIP-specific Vaccibodies were
tested for their ability to bind to NIP-BSA (conjugated
in-house) as previously described [17]. Chemotactic
activity of LD78β (CCL3-L1) Vaccibodies on the mouse
Esb-MP T cell lymphoma was tested by a transwell
plate (Corning), as previously described [16]. The re-
sults (mean + SE of duplicate samples) are presented as
chemotactic index, defined as the fold increase in the
number of migrating cells in the presence of chemotac-
tic factors over the spontaneous cell migration (i.e., in
the presence of medium alone).
Purification of patient tumor Ig protein
Heterohybridomas secreting tumor-specific Ig were gener-
ated from PBMCs of two patients with CLL by standard
procedures [35]. Hybridomas were screened by ELISA
for expression of an Ig of expected H and L-chain iso-
types. H-chain of hybridomas was verified by VH se-
quencing. Hybridomas with VH sequence fully matching
that retrieved from patients’ CLL cells were selected for
further study.
Generation of mouse B lymphoma cells (A20) that
express a stereotyped BCR of HCV-associated B cell
lymphomas
V (D) JH regions from patient 1 (VHP1) and VJL regions
from patient 2 (VκP2) were cloned into independent vec-
tors that had been developed for membrane expression
(but not secretion) of mouse IgDκ [36]. In particular,
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contains downstream of VHP1 the murine germline IgD
sequence (IgDa allotype) in which the 3’ secretory exons
had been eliminated, whereas VκP2 was cloned in the
pMUSmCκ expressing mouse constant κ region and zeo-
cin resistance (Tuva Hereng and Bjarne Bogen, unpub-
lished) to generate VκP2MUSKAP.
A20 BALB/c B lymphoma cells that express an en-
dogenous IgG2aκ and MHC class II (including I-Ed)
were transfected with either or both vectors by electro-
poration, grown in selection medium (G418 and/or zeo-
cin), and cloned by limiting dilution. To screen for A20
transfectants expressing patient VH, cells were stained
with anti-IgD TIB149 (ATCC). Transfectants were se-
lected by flow sorting for high IgD expression followed
by cell culture and re-sorting. Expression of VH1-69 and
VK3-20 was assessed by RT-PCR using the following
primers: for VH1-69, forward GTGCAGCTGGTGC
AGTCT and reverse TCCCTGGCCCCAATAGAAGT;
for VK3-20 forward TTGTGTTGACGCAGTCTCCAG
and reverse TTGATTTCCACCTTGGTCCCT.
As a negative control, we used an A20 cell that expressed
IgDκ with V regions derived from the unrelated syngeneic
Ab2-1.4 hybridoma [36].
Mouse immunization
VB plasmids were purified with Endofree® Plasmid
Mega Kit (Qiagen). 25 μL solution of 0.5 mg/mL VB
DNA in sterile 0.9% NaCl (total 25 μg per mouse) was
injected intradermally in the lower back of mice, on
both sides, followed by electroporation using Derma
Vax™ (Cyto Pulse Sciences, MD, USA). Groups con-
sisted of 3 to 7 mice.
Measurement of antibody responses and assessment of
specificity of anti-scFv antibodies
Blood samples were obtained at different time-points
from the leg vein of vaccinated mice. Sera were tested
by ELISA for reactivity against the patients’ CLL-derived
monoclonal IgM or control isotype-matched IgM, or hu-
man IgG3, as coat. Bound antibodies were detected by
either biotinylated mAb 187.1 (detects murine Cκ), anti-
mouse IgG1a (clone 10.9 BD Pharmingen) or anti-mouse
IgG2aa (clone 8.3 BD Pharmingen). The endpoint titres
were recorded as the final serum dilution giving a signal
above a fixed concentration of alkaline phosphatase-
conjugated goat anti-human IgM (Sigma) or biotinylated
mouse anti-human IgG (HP6017).
Sera were also used to stain PBMC from different CLL
patients. Bound mouse antibodies were detected with bi-
otinylated mAb 187.1 followed by streptavidin PerCP.
Surface Ig expression by CLL cells was assessed by Cell-
Quant (Biocytex), measuring the average Ig surface
number by analyzing 20,000 cells.Sera from immunized BALB/c or B10.D2.C-TCRaa/Bo
(H-2d IgH-Cb) mice were used to stain A20 transfectants
expressing human IGHV1-69, or human IGKV3-20, or
both. Following blocking with PBS with BSA and heat-
inactivated rat serum, transfectants were admixed with
sera. Bound mouse antibodies were detected with bio-
tinylated anti-mouse IgG1a for BALB/c sera or anti-
mouse IgG2ab for B10.D2.C-TCRaa sera.
Injection of transfected A20 cells in immunocompetent mice
BALB/c mice were injected s.c. with 3 × 106 parental A20
cells or with A20 cells stably transfected with either VH1-
69, or VK3-20 or both, and followed up for tumor growth.
Statistical analysis
Analysis of variance and regression analysis were con-
ducted on all treatment arms. Results are presented as
comparison of slopes of the antibody response in differ-
ent treatment arms across serum dilutions.
Results
Identification and assembly of CLL-derived V genes into
Vaccibodies
The characteristics of the patients’ CLL cell BCR in-
cluded in this study are presented in Table 1. The CLL-
specific V regions were identified in each case as identical
VDJH and VJL sequences repeatedly obtained after clon-
ing of PCR products. The corresponding scFv was
then assembled for two patients (CLL106 and CLL107)
and cloned into the antigenic unit of various VB scaf-
folds. According to previously published results on other
Vaccibodies [10,13-17], transiently transfected HEK 293
cells were expected to secrete homodimeric fusion pro-
teins consisting of i) two targeting units: either mouse
scFv specific for mouse MHC class II molecules (I-Ed),
or the hapten NIP (non targeted negative control), or
two human CCL3 (LD78β isoform) chemokine moieties,
ii) two dimerization units: human hinge-CH3 held to-
gether by disulfide bonds and non-covalent interactions,
and iii) two antigenic units: either human scFv of CLL
origin (patients CLL106 and CLL107) or prototypic ste-
reotyped VH and VL associated with HCV-associated B
lymphomas (Figure 1A). ELISA on supernatants of tran-
siently transfected 293E cells demonstrated similar
levels of secretion of the fusion protein for each con-
struct (Figure 1B and data not shown). The targeting
units of the respective bivalent VB proteins retained
their functional properties since anti-MHC II VB bound
MHC class II + ve A20 cells (Figure 1C) and LD78β VB
chemoattracted mouse Esb/MP cells (Figure 1D). Non tar-
geted anti-NIP VB neither bound A20 cells (Figure 1C)
nor chemoattracted Esb/MP cells, whereas it bound
NIP-BSA in ELISA (data not shown). Taken together,
these results of Figure 1 are consistent with previous
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Figure 1 Characterization of fusion vaccines used in this study. (A) Schematic structure of a homodimeric vaccine fusion protein (Vaccibody,
VB). Targeting, dimerization and antigenic units are indicated, as are the different moieties expressed in the various units. MHC class II targeted
(I-Ed-specific) and non-targeted (NIP-specific) constructs are denoted (FvI-EFvPn)2 and (Fv
NIPFvPn)2, respectively, whereas LD78β VB are denoted
(LD78βFvPn)2. where Pn indicates patient number. (B) Detection of VB proteins in supernatants of transfected HEK 293E cells in an ELISA specific
for hγCH3. (C) Binding of MHC class II-targeted VB to I-Ed+ A20 cells. (D) LD78β VB displays dose-dependent chemotactic activity on lymphocytic
Esb/MP cells. Recombinant LD78β was used as positive control.
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other antigenic units [10,13-17].
Analysis of the antibody responses induced by DNA
Vaccibody immunization
Sera from mice that had been immunized once with
different VB constructs were tested for recognition of
the corresponding tumor Ig by ELISA at week 2, 4 and
9 after immunization. To this end, the BCR of patient
CLL106 was expressed by rescue hybridoma as a se-
creted IgM used for coating ELISA plates. Improved
antibody responses were observed in all mice immunized
with either MHC class-II- or chemokine receptor-targeted
VB, as compared with mice immunized with the control
non targeted NIP-specific VB (Figure 2A and data not
shown). By week 9, the effect of targeting was less striking
but nevertheless observed, in keeping with previous find-
ings [10,13,16,17,37]. Induction of antibodies was specific
for the antigenic unit in the immunogen since sera from
mice that had been immunized with VB encoding patient
CLL107 scFv Id as antigenic unit did not recognize patient
CLL106 IgM in ELISA at any time point (Figure 2A and
data not shown). In order to assess the nature of the anti-
body response induced by the different Vaccibodies, the
IgG1 and IgG2a components were compared at different
time points. The targeting unit appeared to influence anti-
body isotype since a trend toward a predominant IgG2a
or IgG1 antibodies were observed in sera of mice that had
been immunized with chemokine receptor- or MHC classII-targeted VB, respectively, starting from week 4 and
peaking at week 9 (Figure 2B and data not shown), in line
with previous reports [10,15,37,38].
We next investigated if sera from the targeted VB
106-immunized mice bound BCR on CLL cells. Sera
were admixed with PBMCs from patient CLL106 as well
as four other CLL patients (Table 1). Sera from all im-
munized mice had antibodies binding 106 CLL cells in
titres >200 (Figure 3A and data not shown). Strikingly,
the sera also cross-reacted with CLL cells from CLL103
and to a lesser extent with CLL111 CLL cells, but not
with CLL107 and CLL116 CLL cells (Figure 3B). The
CLL cells from these two patients (CLL103, CLL111)
expressed Vλ and VH genes of the same family as
CLL106 (Table 1 and Figure 3). At the protein level,
the L chain V-regions of CLL111 and CLL103 CLL cells
were close to identical with CLL106 (Figure 3C). More-
over, the VH were of the same family (IGHV3) and
CLL cells were identical to CLL106 in 82% (CLL103)
and 83% (CLL111) of the VH amino acids (Figure 3D).
The results suggested that the elicited antibodies cross-
reacted to homologous sequences or combinatorial VH/
VL determinants. The lower level of staining of CLL111
cells could be explained by IGLV3-21 being diluted by a
second productive L chain rearrangement found in these
CLL cells (IGKV3-20*01 F/IGKJ1*01 F) expressed by the
vast majority of cells (Table 1, Figure 3B and data not
shown), reducing the level of VL and VH/VL determi-
nants on these cells.
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Figure 2 Levels of anti-Id antibodies elicited by DNA vaccination and electroporation depend upon ability of translated fusion proteins
to target APC. (A) Mice received a single DNA immunization plus electroporation of the indicated plasmid DNA or NaCl control. Sera obtained
at different time-points were tested in ELISAs for antibodies binding CLL106 monoclonal IgM/λ purified from heterohybridomas established from
patient CLL106 CLL cells. Results at week 2, 4 and 9 after single immunization are shown. Mean ± SEM are plotted, n/group = 7. * p < 0.05 for
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levels of surface Ig (data not shown). The lack of unspe-
cific staining due to recognition of human IgM by
mouse antibodies was ruled out by lack of staining of
patient CLL107 and CLL116 cells (Figure 3B and data
not shown).
Construction of a mouse model for B cell lymphomas
expressing a prototypic human HCV-associated
stereotyped BCR
A sizeable proportion of B cell lymphoproliferative dis-
eases, particularly HCV-associated B cell lymphomas,
express IGHV1-69 and IGKV3-20 [18,20]. Thus, we iden-
tified prototypic IGHV1-69 and IGKV3-20 genes obtained
from two different HCV-associated lymphomas selected
as having a representative predicted amino acid se-
quence. Hence, we constructed a mouse model suitable
for the development of an Id vaccine expressing these
stereotyped V regions. In order to reduce the possibility
that immunocompetent mice spontaneously rejected
cells expressing human Ig, prototypic IGHV1-69 and
IGKV3-20 V (D) J from patient 1 and 2, respectively,
were cloned with mouse δ and κ constant regions, re-
spectively, and transfected into the BALB/c B cell lymph-
oma A20. It should be noted that the mouse δ construct
was engineered so that it was only expressed on themembrane but was not secreted [36]. The following three
human/mouse Ig transfectants were generated: (i) A20
IGHV1-69, transfected with IGHV1-69 alone, (ii) A20
IGKV3-20 transfected with IGKV3-20 alone, and iii)
A20 IGHV1-69/IGKV3-20 transfected with both IGHV1-
69 and IGKV3-20 (Figure 4A). In addition to the trans-
fected chains, A20 cells express an endogenous IgG2a,κ
and all types of transfected cells retained expression of
the endogenous BCR (data not shown). Surface expres-
sion of transfected IGHV1-69-mouse Cδ hybrid gene
was confirmed by flow cytometry (Figure 4A). Note also
that the expression of IgD/IGHV1-69 in the absence of
IGKV3-20 (Figure 4A, bottom right) was detected at
the same (or higher) levels than in the presence of
VK3-20 (Figure 4A, top right). As A20 cells express en-
dogenous κ chains (κEndo) IgD/ IGHV1-69 could pair
with this κEndo.
The lack of a validated anti-human IGKV3-20 mAb
negated flow cytometric analysis of VΚ expression, which
was therefore screened by RT-PCR (Figure 4B). Thus,
no formal proof of surface expression of the human
IGHV1-69/IGKV3-20 pair on transfected A20 cells could
be obtained, although this is likely to be the case. Trans-
fectants bona fide expressing human IGHV1-69/IGKV3-
20 were sorted three times to further select efficiently
transfected cells.
AB
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D
Figure 3 Antibody responses elicited by targeted Id-DNA vaccines recognize the patient’s CLL cells and cross-react to other patients’
CLL cells expressing highly similar monoclonal Ig. (A). Sera from mice that had been DNA vaccinated with the patient CLL106-specific VB
targeted by LD78β, were tested in flow cytometry for binding to patient 106 CLL cells. Shaded histogram, serum from mock immunized mouse,
black line serum from a representative immunized mouse (n = 5/group). (B) The same sera were tested for cross reactivity against a panel of CLL
cells obtained from different patients (see Table 1). Data for a representative mouse serum are shown at 1:200 dilution. (C) & (D) Alignment of
VL (C) and VH regions (D) from patients CLL106, CLL103 and CLL111. V regions amino acid sequences were aligned using GeneDoc. Amino
acids are color coded according to charge (negative: D, E; positive: H, K, R), or the chemical properties of side chains (i.e. amide: N, Q; alcohol:
S, T; aliphatic: L, I, V; aromatic: F, Y, W; small size: A, G; sulfur atom: M, C; or other: P, see key for color code).
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with Vaccibodies expressing a stereotyped BCR found in
HCV-associated B lymphomas
Mice were immunized with LD78β-VB having an anti-
genic unit comprised of prototypic HCV-associated B
lymphoma BCR with IGHV1-69 and IGKV3-20 linked
in a scFv format. In terms of secondary detection of
bound murine antibodies, it is notable that A20 cells en-
dogenously express surface IgG2a, precluding detection
of bound serum IgG2a. Immunized mice had low levels
of serum IgG1 antibodies that stained IGHV1-69/
IGKV3-20 A20 cells (data not shown). To be able to
visualize IgG2a responses, we also immunized a strain of
mice that differ in Ig H-chain allotype, permitting use of
anti-IgG2a allotype-specific antibodies in flow cytometry.
Hence, B10.D2.C-TCRαa (H-2d, Ig haplotype IgH-Cb)
mice (see Materials) were immunized with the sameVB as above. Sera from mice that had been immunized
once bound A20 IGHV1-69/IGKV3-20 as well as A20
IGHV1-69 cells, but not untransfected A20 or A20
IGKV3-20 cells (Figure 5A). Antibody titres were more
than 1:3200 (Figure 5B). Note that as A20 expresses en-
dogenous gamma chains (γEndo) as well as κ (κEndo), the
latter cells could express γEndo-chains paired with
IGKV3-20. Similarly, the IGHV1-69 transfectant could
express this heavy chain paired with κEndo. We further
tested sera for binding to DG-75 [31], a sIgMκ+ Burkitt’s
lymphoma cell line that expresses very similar IGKV3-
20 (93.8% identity of the Vκ amino acids) but dissimilar
VH (IGHV3-23) (only 51.5% identity of VH amino acids)
(Figure 5C and data not shown). In spite of the expres-
sion of the correct IGKV3-20 L chain, sera failed to stain
these cells, suggesting that the elicited antibodies were
predominantly specific for VH. However, some anti-Id
Figure 4 Construction of mouse B lymphoma cells that express
surface chimeric BCR with stereotyped V regions of patients
with HCV-associated NHL. (A) Detection of δ-chains expressing
IGHV1-69 on A20 cells transfected with IGHV1-69 and IGKV3-20 (top
right), IGVH1-69only (bottom right), IGKV3-20only (bottom left) and
untransfected control (top left). IgD staining is shown. Endogenous
IgG2aκ is not shown. (B) Expression of human IGKV3-20 was verified
by RT-PCR. IGHV1-69 and IGKV3-20 amplification: lane 1: parental
A20; lane 2: A20 IGHV1-69; lane 3:, A20 IGHV1-69/IGKV3-20, lane 4:
A20 IGKV3-20; lane 5:,IGHV1-69 or IGKV3-20 encoding plasmid; lane
6: no template DNA. 100 bp DNA ladder was used.
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terminants since A20 cells expressing VH1-69/VK3-20
stained brighter than A20 cells expressing only VH1-69.
This result was obtained with sera from 4 out of 5 mice
(Figure 5A, arrows/circles), indicating a contribution of
combinatorial VH/VL epitopes. The sera from all mice
failed to bind A20 cells expressing an unrelated IgD
(Ab2-1.4, see Methods and Figure 5C), as well as a
Burkitt’s lymphoma control (PA682, see Methods).Growth of transfected A20 cells in BALB/c mice
Three BALB/c mice per group were injected s.c. with 3
× 106 either parental A20 cells or IGHV1-69/IGKV3-20
transfected A20 cells. Two out of three mice that had
been injected with parental A20 cells developed tumors,
whereas no mice that had been injected with IGHV1-69/
IGKV3-20 A20 cells developed tumors, presumably due
to immunogenicity of the xenogeneic (human) Ig V re-
gions sequences in mice. These results are reminiscent
of our previous finding in multiple myeloma, where the
tumorigenicity of MOPC315.36 was decreased by stable
expression of human V genes [17]. The lack of tumori-
genicity of the A20 transfectant in immunocompetentmice precluded both prophylactic and therapeutic anti-
tumor vaccination experiments.
Discussion
Herein we describe experiments aimed at generating Id
vaccines for therapeutic Id vaccination of groups of pa-
tients with B cell malignancies expressing stereotyped
BCRs. First, we demonstrate the feasibility of construct-
ing fully human Id Vaccibodies with maintenance of
both Id epitopes and functionality of targeting units (i.e.,
human CCL3 chemokine LD78β that cross-react with
mouse CCRs) [16]. Similar to fully murine and chimeric
mouse/human vaccibodies, targeting antigen delivery to
APC by human chemokine resulted in augmented im-
mune responses in mice as compared with non-targeted
control DNA Vaccibodies [16]. Since these vaccines are
fully human and isoform LD78β of human CCL3 bind
cells expressing Rhesus macaque CCR5 [16], they are
suited for both preclinical immunogenicity and regula-
tory toxicology studies in view of clinical application. It
may be anticipated that targeting scFv Id to APC by
LD78β could result in increased anti-Id responses in pa-
tients. Furthermore, DNA vaccination combined with
electroporation is already employed in clinical trials for
melanoma and prostate cancer, with mild to moderate,
reversible side effects [39].
Second, we explore a complementary approach to fur-
ther streamline clinical application of Id vaccine for B
cell malignancies.
Antibodies elicited in mice by Id DNA Vaccibodies
constructed for a CLL patient showed cross-reactivity
with CLL cells from some other patients. The most
plausible explanation is that a fraction of mouse anti-
bodies recognized epitope(s) displayed by the VL and/or
VL/VH of the cross-reactive CLLs, since the CLL cells
expressed nearly identical IGLV3-21 and similar IGHV3
family genes. With the HCV-NHL construct, the in-
duced antibodies bound the transfected A20 cells but
failed to bind a Burkitt’s lymphoma expressing the cor-
rect Vκ but not the corresponding VH, indicating a
dominant anti-VH response. Even so, a contribution of
the Vκ was however detected as VK3-20+VH1-69+ trans-
fectants stained brighter than VkEndogenous/VH1-69only
cells (that express an endogenous Vκ), suggesting re-
sponses towards VL/VH combinatorial idiotypes. Taken
together, it is suggested that immunization of mice with
fully human targeted scFv Id DNA vaccines could elicit
antibodies that may react with either VL, or VH, or VL +
VH, the relative proportions differing from case to case.
The above observations suggest the possibility of con-
structing vaccines covering molecularly identified sub-
groups of patients with B cell malignancies. This idea is
supported by evidence of Id cross-recognition by anti-Id
mAb [40] as well as cross-reactive responses observed in
Figure 5 Chemokine-receptor-targeted Vaccibodies expressing HCV-associated lymphoma prototypic BCR elicit high titer antibodies
that bind transfected A20 cells expressing HCV-associated lymphoma prototypic BCR. Five Ig haplotype IgH-Cb mice (B10.D2-TCRαa) were
DNA vaccinated with LD78β VB having as antigenic unit prototypic HCV-associated B lymphoma BCR (with IGHV1-69 and IGKV3-20 linked in a
scFv format), followed by electroporation. (A) Sera containing IgGb obtained 21 days later were used at 1:400 dilution to stain both transfected
and parental A20 cells (that express Ig haplotype IgH-Ca), bound IgG2ab was detected with an mouse anti-IgG2ab mAb. Representative staining
are shown of immunized sera (line) or control (gray filled). Peak channels are indicated in the second (arrows) and third panels (line-circles). For
comparison, an arrow in the third panel indicates the peak channel from the second panel. (B) Antibody titres of a representative mouse. (C) Left:
sera from a mock immunized (gray filled) or a representative immunized mouse (line) did not stain cells from the IGKV3-20+ Burkitt’s lymphoma
(DG-75), or A20 expressing syngeneic V regions on BALB/c IgD,κ scaffold (Ab2-1.4). Right: Comparison of the VH amino acid sequence of DG-75
and IGHV1-69. Amino acids are indicated as in Figure 3.
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Id vaccine should elicit a cross-reactive immune re-
sponse effective against unrelated B cell tumors express-
ing V regions of the same families, provided that the
pattern of somatic mutations is similar between individ-
ual tumors. In this respect, the application of criteria de-
veloped for clustering stereotyped BCR as based on
HCDR3 sequences only [27] do not fully meet the need
for identifying patients amenable to immunization with
such vaccines, as immune responses following vaccin-
ation may be directed to determinants located elsewhere
in the V regions [45-47]. Hence, similarity across the
whole V regions should be evaluated. In principle, stain-
ing of lymphoma sections or single cell suspensions ob-
tained from biopsy with serum from mouse that had
been immunized with the intended Id vaccine could be
able to identify candidate patients.
Evidence of clinical benefit by Id vaccination has been
obtained so far only upon immunization with whole Ig
protein vaccine [2,3], thus displaying to the host immune
system both tumor-specific VH and VL. Therefore, con-
sidering that IGHV1-69 is often the partner of IGKV3-
20 in HCV-related NHLs [18,20], a prototypic BCR for
a subset of HCV-associated NHL was cloned, inserted
into VB format and used to DNA immunize mice. We
chose IGHV and IGKV from unrelated lymphomaspurposely considering the possible use of such Vaccibo-
dies as off-the-shelf, subgroup-specific vaccines. In fact,
while HCV-associated NHL express IGHV1-69 and
IGKV3-20 proteins with high similarity in the frame-
work regions, the presence of several differences in
the amino acid sequence of the CDR regions makes it
difficult to select a one-for-all IGHV-IGKV pair. On
these grounds, we selected IGHV1-69 and IGKV3-20
proteins as prototypic on the basis of their representa-
tivity of the FR regions among HCV-associated lymph-
omas. Our results show that such an artificial targeted
DNA Id vaccine elicits antibodies in mice that bind
mouse B lymphoma cells transfected with the H and L
chain genes composing the artificial BCR. Whether
these antibodies bind human IGHV1-69/IGKV3-20 B
lymphomas remains to be investigated pending sample
availability.
From a translational standpoint, the possibility of
using DNA vaccines encoding scFv with the potential to
elicit cross-reactive immune responses is not restricted
to the IGHV1-69/IGKV3-20 combination, as similar fea-
tures of conserved V regions usage have been detected
in other B cell malignancies. Thus, one can envision tai-
lored Id vaccines for each major stereotyped subset iden-
tified. To estimate the number of patients with B-cell
malignancies that could be immunized with off-the-shelf
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quences of idiotypic VH and VL genes expressed by low
grade B-NHL, autoimmunity-associated lymphoprolifera-
tions (e.g. HCV-related NHL, mixed cryoglobulinemia,
Sjögren’s syndrome) and CLL is currently being set up
with the aim of identifying subgroups of tumors charac-
terized by the expression of molecularly correlated Id
proteins on the basis of the degree of sequence conser-
vation among patients (R Dolcetti, unpublished results).
However, stereotyped BCR sequences appear to be disease-
biased. In CLL, shared V regions are in most cases
unmutated [25,26,48,49] whereas in other B cell tumors
(e.g., HCV-associated lymphomas, MALT lymphomas)
somatic mutations are more frequent [18,20,21]. There-
fore, from an immunological standpoint, the yet un-
answered question as to whether the host immune system
can recognize V region sequences in germline configuration
following Id vaccination is of paramount relevance for the
possibility of applying Id vaccines, whether individual or
subgroup-specific [50].
It should be stressed that certain human B cell malig-
nancies have not been described to express stereotyped
BCR. One example is multiple myeloma cells that carry
high loads of somatic mutations in their V regions, con-
sistent with an origin from post germinal center B cells
[51]. In a previous report, we demonstrated that mice
DNA-immunized with hybrid mouse/human Vaccibo-
dies expressing scFv of either of four myeloma patients
induced anti-Id antibodies that bound the corresponding
myeloma protein with little cross-reactivity despite the
fact that the BCR of two patients used the same IGHV
and IGHJ genes [16]. Thus, in the case of multiple mye-
loma, V regions of monoclonal Ig express unique Ids
with little cross-reactivity, at least as defined by anti-
bodies elicited by APC-targeted DNA Id vaccines.
The discussion above has focused on antibodies elicited
by APC-targeted DNA Id vaccines since anti-Id antibodies
have been linked to anti-lymphoma activity both in pas-
sive and active immunotherapy [52,53]. However, MHC-
restricted, Id-specific T cells have been shown to display
anti-lymphoma activity and to eradicate B cell tumors
[43,47,54,55]. scFv in the vaccine contains Id-sequences
available for MHC presentation. T cell responses were
not investigated in this study as they would have been di-
rected against xenogeneic Ig sequences thus having no
semblance to the clinical situation. Nevertheless, it can
be speculated that subgroup-specific vaccines can elicit
cross-reactive Id-specific T cell responses which may or
may not be accompanied by cross-reactive humoral
responses, as has recently been suggested with HCV-
associated B cell lymphoma IGKV3-20 [56], However,
patients differ in polymorphic HLA molecules and are
therefore expected to present different sequences of
V regions of CLL/B lymphoma BCR on their HLAmolecules, thus making the possibility of cross-reactive
T cell responses less common as compared with anti-
body responses. Also, based on mouse studies, T cell
tolerance to the CLL/B lymphoma BCR is likely to limit
T cell responsiveness in humans to a greater extent
than humoral responses.
Conclusions
Herein we demonstrate the feasibility of constructing fully
human Vaccibodies that target scFv Id to mouse APC
in vivo enabling enhanced immune responses. The strik-
ing similarity of amino acid Id sequence found across
different subgroups of patients affected by molecularly
identified B cell malignancies could be exploited to pre-
pare subgroup-specific vaccines. As opposed to patient-
specific vaccines, such “off-the-shelf” vaccines could
reduce the number of tailor-made Id DNA vaccines allow-
ing substantial time and cost savings.
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